Canada-based leading medical device and software company MedX Health has signed a Memorandum of Understanding (MoU) with GCC’s major healthcare-focused company Al Zahrawi Medical Supplies (Al Zahrawi) on a two-phase commercialization pilot and distribution deal for MedX’s cutting-edge DermSecure Screening Platform.
The three-month pilot will involve an estimated 1,000 patients at four dermatology and oncology clinics in Abu Dhabi and Dubai. Upon the successful completion of the two phases, the MedX DermSecure Screening Platform will become more widely available at clinics and healthcare facilities across the UAE, according to the company.
As the largest distributor of medical devices in the GCC region, the partnership with Al Zahrawi positions MedX for continued growth in other Middle Eastern markets including Saudi Arabia, Qatar, Oman, and Bahrain.
This is the latest in a series of commercialization pilots that MedX has recently undertaken in Europe and the Middle East as part of its worldwide commercialization plan, after pilots in the Netherlands, Italy, and Turkey.
Mr. David Fawzy Yassa, Business Development Director at Al Zahrawi said, “MedX’s teledermatology platform meets these high standards, with a proven ability to improve outcomes for dermatology patients. We’re eager to work with MedX to bring the platform to more patients across the UAE market and other GCC nations.”
Mr. Sylvain Desjeans, MedX CEO commented that “this pilot is a significant step forward in growing MedX’s global presence, particularly among countries in the GCC region. During this time of rapid growth for our company, we look forward to working with trusted partners like Al Zahrawi to expand our global footprint and improve more patient outcomes.”
“Our pilot in the UAE is an important foothold in the GCC region – it represents the first of six markets we want to penetrate in the Middle East. Following the successful completion of this UAE pilot, we’ll be seeking other similar opportunities in Saudi Arabia and other GCC nations in the months ahead,” added Mr. Naman Demaghlatrous, MedX Managing Director of Europe, Middle East, and Africa.
